Scientists at Lankenau Institute for Medical Research (LIMR) and Dynamis Therapeutics recently published a study entitled “Meglumine Exerts Protective Effects Against Features of Metabolic Syndrome and Type II Diabetes” in the leading online biomedical research journal PLOS ONE. In their study, they report the discovery that meglumine, an FDA approved derivative of the sugar-free sweetener sorbitol can reduce high blood sugar and triglycerides, improve muscle function and reduce diabetic complications.
Diabetes and the pre-diabetic condition called metabolic syndrome are becoming increasingly common medical issues in the United States, with almost 19 million people diagnosed with diabetes and as many as 7 million undiagnosed cases. Ongoing clinical management of blood sugar is critical, as many diabetic patients with uncontrolled blood sugar develop heart disease, blindness, kidney disease, nervous system damage and other life-threatening problems.
Sorbitol, a sweet substance found in fruit that is used in sugar-free chewing gum and candy, has been known to reduce blood sugar by stimulating its absorption by muscle. However, clinical studies have shown that sorbitol cannot be used to treat diabetes or metabolic syndrome because it can cause uncomfortable gastrointestinal side effects, and may even increase certain diabetic complications such as nerve damage, cataracts and retinopathy.
In looking for a better alternative to sorbitol without the undesirable side effects, LIMR Research Assistant Professor Arturo Bravo-Nuevo, PhD and his colleagues tested the sorbitol derivative meglumine for its ability to control high blood sugar. In their preclinical study, the LIMR and Dynamis researchers discovered that meglumine produced striking effects on muscle associated with anti-diabetic effects. Meglumine markedly reduced triglyceride levels in the blood and liver along with the onset of diabetic kidney disease. Notably, muscle stamina and glycemic (sugar) control were both improved, without any apparent side effects including any of the gastrointestinal issues produced by sorbitol.
As Dr. Bravo-Nuevo noted, “It is exciting that one safe supplement might not only control high glucose and triglyceride levels but also prevent kidney deterioration and improve muscle stamina at the same time.”
The findings of the LIMR and Dynamis research teams support further clinical study of meglumine as a safe, inexpensive supplement for counteracting metabolic syndrome, improving muscle function, and reversing diabetes and its complications. Meglumine is currently used as a binding agent in pharmaceutical compounds to improve their stability and absorption, so it has a safe, benign history and its use has already been accepted by the FDA. Given its positive effects observed on the muscular system, meglumine may also have the potential to serve as an exercise supplement for preventing muscle fatigue and perhaps increasing strength.
Dynamis Therapeutics, Inc. is a biopharmaceutical company that is developing proprietary new drugs to treat chronic inflammatory disease. Its proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone (3DG). Scientific evidence suggests that elevated 3DG causes metabolic, neurological, and dermatological diseases, ranging from diabetic retinopathy (blindness) and nephropathy (kidney disease) to inflammatory skin conditions and aging. The Company’s first medical products are drugs against dry eye and the complications of diabetes. For more information, please see dynamis-therapeutics.com.
Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of Lankenau Medical Center. Part of Main Line Health, LIMR is one of the few freestanding, hospital associated medical research centers in the nation. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer, heart disease, diabetes and autoimmune disorders. This information is used to help improve diagnosis and treatment of these diseases as well as find ways to prevent them. LIMR is also committed to extending the boundaries of human health and well-being through technology development and the training of the next generation of scientists and physicians. To learn about LIMR, visit limr.org.
Founded in 1985, Main Line Health (MLH) is a not-for-profit health system serving portions of Philadelphia and its western suburbs. At its core are four of the region’s respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s premier facilities for rehabilitative medicine, Bryn Mawr Rehab Hospital; Mirmont Treatment Center for drug and alcohol recovery; and Main Line Health HomeCare & Hospice, a home health service. Main Line Health also consists of Main Line HealthCare, one of the region’s largest multi-specialty physician networks, and the Lankenau Institute for Medical Research, a non-profit biomedical research organization located on the campus of Lankenau Medical Center. Main Line Health also consists of four outpatient health centers located in Broomall, Collegeville, Exton and Newtown Square. Main Line Health hospitals, with more than 10,000 employees and 2,000 physicians, are the recipients of numerous awards for quality care and service, including recognition among Truven Health Analytics’ list of Top 100 Hospitals and top 20 percent of health systems in the nation, and Magnet®, the nation’s highest honor for nursing excellence. Main Line Health is among the area’s leaders in medicine, providing advanced patient-centered care, education and research to help our community stay healthy.
© 2015 Main Line Health